The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mm content recommended for you
Video series
During the Multiple Myeloma Hub Steering Committee Meeting in November 2022, key opinion leaders met to discuss how to identify high-risk patients with multiple myeloma. The recorded discussion was chaired by Professor Sagar Lonial and featured María-Victoria Mateos, Morie Gertz, Paul Richardson, Heinz Ludwig, and Hermann Einsele.
This meeting opens with a discussion on genetics and clinical characteristics and how they inform risk status. Richardson notes that defining patients by genetic risk status alone may be insufficient and the inclusion of clinical parameters should be used to accurately stratify this group. For example, cases harboring the translocation 4;14 or 17p may both be high risk but respond to treatments, such as transplant, differently. The members go on to discuss time to response and MRD status as important clinical factors determining risk; followed by an examination of mutations and circulating plasma cells as predictors of poorer outcomes, with a focus on 1q and translocation 11;14.
There is a need to consider “functional” high-risk patients, including those who progress in the first few years of treatment without high-risk genetics, to establish high-risk pretreatment features, and to consider “post hoc” variables (e.g., time to response) that can also affect outcome and prognosis. There is also a need to consider optimal treatments for patients with special considerations, such as extramedullary disease, and patients who return to a state of monoclonal gammopathy of unknown significance after successful treatment.
The meeting concludes with a discussion on the therapeutic approach for high-risk patients with a consideration for equal access to treatment options.